# Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.

Study · id `cardio:ct-nct07201688` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07201688](<https://clinicaltrials.gov/study/NCT07201688>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07201688

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 890 participants.

## Technical summary

Registry record NCT07201688. Randomized; triple masking; primary purpose treatment. Start 2025-11-30 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 890 participants (planned count; ClinicalTrials.gov record NCT07201688, source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)
- Started: 2025-11-30 (actual) (ClinicalTrials.gov record NCT07201688, source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07201688, source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07201688, source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07201688, source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07201688-2025-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
- Acronym: TRACE-LATE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): rhTNK-tPA
- Intervention (Drug): Placebo
- Lead sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (`cardio:org-cspc-mingfule-pharmaceutical-guangzhou-co-ltd`)

## Provenance

Content hash: f948ce09702b4ca008304e9db2f917d5a6a004f3a9d4ac474a033eefacd46a94
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
